Alodan

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Alodan

Quick Facts

Property Description
Active ingredient Allopurinol
Form Tablet (Oral), Solution (Intravenous)
Pharmacological class Xanthine Oxidase Inhibitor (XOI)
Common purpose To reduce Uric acid production
Origin Synthetic (Purine analogue)

Alodan is a synthetic prescription medication whose active ingredient is Allopurinol, classifying it as a Xanthine Oxidase Inhibitor (XOI), a category of drugs primarily used to manage conditions related to elevated Uric acid. The preparation is a single-ingredient, synthetic agent whose primary purpose is metabolic control. Alodan is specifically presented as an oral tablet, which is the most common and recognized form for long-term hyperuricemia management worldwide.

Pharmacological Type and Mechanism Concept

Alodan belongs to the pharmacological class of Uric Acid Reducing Agents. Allopurinol is chemically identified as a Purine analogue, meaning its structure is similar to naturally occurring purine bases in the body, which allows it to target a specific metabolic step. Allopurinol effectively inhibits the enzyme Xanthine Oxidase (XO), which is responsible for the final steps of converting purines into Uric acid. By blocking this enzyme, the medicine helps to consistently limit the formation of Uric acid throughout the body.

The systemic effect of Inhibition of Xanthine Oxidase is what defines the drug's action. Allopurinol is metabolized into Oxypurinol, which sustains this inhibitory action. This mechanism directly manages the underlying metabolic imbalance, helping to maintain Uric acid concentration at a lower level.

Composition and Available Forms

The composition of Alodan relies solely on the active pharmaceutical substance Allopurinol. While Alodan is typically marketed as an oral tablet for oral administration, the active ingredient Allopurinol is also formulated as a sterile solution for injection for intravenous administration. This injectable form is reserved for urgent situations or when oral intake is not feasible, reflecting its versatility in patient care. Allopurinol remains a standard, foundational treatment for hyperuricemia management across multiple patient groups. The drug is considered a reliable and well-established option for managing conditions linked to excessive Uric acid.

What side effects are possible with Alodan?

Possible Side Effects and Safety Information

The safety profile of Alodan, whose active ingredient is Allopurinol, is documented by government regulatory bodies, classifying adverse reactions by frequency and the body system affected.


Frequency-Classified Adverse Reactions

Adverse reactions are formally categorized based on the likelihood of their occurrence, as outlined in official prescribing information.

  • Common: The most frequently reported adverse reaction is skin rash, which can range from mild to severe, and an increase in blood thyroid stimulating hormone (TSH) levels.
  • Uncommon: Reactions such as hypersensitivity reactions, nausea, vomiting, diarrhea, and abnormal liver function test results are documented as less common.
  • Rare: Rare adverse effects include severe cutaneous adverse reactions (SCARs) like Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), and serious liver injury, such as hepatitis.

Serious and Systemic Safety Considerations

Official documents highlight rare but potentially serious systemic reactions. These include the severe allergic condition known as Allopurinol Hypersensitivity Syndrome (AHS) and serious blood disorders such as agranulocytosis and aplastic anaemia. Renal failure or insufficiency is also noted as a clinically significant adverse reaction.

Safety notes specify that patients with decreased renal function are at an increased risk of severe hypersensitivity reactions. The regulatory label states that treatment must be immediately discontinued at the first appearance of any skin rash due to the potential for it to progress to a severe reaction. An increase in acute gout flares is commonly observed upon the initiation of therapy.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory prescribing information provides guidance on severe drug exposure. Acute massive overdosage has been documented to present with manifestations focused on the gastrointestinal tract, primarily including nausea, vomiting, and diarrhea, alongside central nervous system effects such as drowsiness.

The critical risk following excessive exposure involves the potential for life-threatening systemic toxicity, often linked to the accumulation of the active metabolite, oxipurinol. Severe outcomes documented in official labeling include acute kidney and hepatic failure, as well as seizures and Severe Cutaneous Reactions (SJS, TEN, DRESS).

Immediate medical help must be sought for any suspected massive ingestion. Furthermore, the drug must be discontinued immediately and emergency medical attention must be sought at the first appearance of a skin rash or any other sign indicating a hypersensitivity reaction (e.g., fever or swelling).

Regulatory documentation states that no specific antidote is known for overdose. Management is officially defined as symptomatic and supportive care. In cases of severe exposure, procedures such as haemodialysis may be utilized to effectively remove the drug and its metabolite from the system. Individuals with decreased renal function are explicitly noted to be at a significantly increased risk of developing severe toxicity.

Therapeutic Uses of Alodan

Alodan is generally considered a foundational medication used in the long-term management of clinical conditions driven by excessive uric acid in the body. Its therapeutic benefits center on managing the conditions and symptoms related to the buildup of uric acid.


Main Uses and Therapeutic Benefits

This medication is relevant across three primary areas of patient care: the control of chronic gout, the prevention of recurrent uric acid kidney stones (nephrolithiasis), and the management of high-risk hyperuricemia in contexts like cancer therapy.

“Its purpose is to maintain stable uric acid levels, which generally supports the management of recurrent symptoms.”

In the chronic setting, Alodan is commonly used to provide sustained condition management for gout, which involves managing episodic joint inflammation and swelling. It is also applied to assist with the reduction of uric acid deposits (tophi). For high-risk scenarios, it is used as a key preventative strategy to manage the risk of a sudden, dangerous surge of uric acid (Tumor Lysis Syndrome), which may assist with maintaining functional stability in the kidneys during intensive therapeutic phases. The treatment is used for managing the recurrence of future painful attacks and contributes to easing the overall symptom load, which may help patients cope more steadily with symptom fluctuations.


Quick Fact: Relief for Chronic Gout
Primary Goal Long-term Condition Management
Symptom Domain Recurrent, disabling joint inflammation
Key Benefit Supports the management of recurrent joint inflammation
Scenario of Use Long-term maintenance after an acute attack has resolved

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Official Eligibility and Restrictions

Alodan (Allopurinol) is officially intended for use in adults with established conditions like manifest gout and certain uric acid nephropathies, and for the management of hyperuricemia in specific adult and pediatric patients undergoing cancer therapy. Regulatory documents define eligibility based strictly on patient condition, age, and physiological status.

Classification Eligibility Rule (Official Labeling)
Absolute Contraindication Patients with known hypersensitivity to Allopurinol must not use the medicine.
Initial Treatment Restriction Therapy should not be started during an acute attack of gout [EMA/FDA].
Organ Function Status Use requires extra caution and reduced doses in patients with impaired renal function or hepatic impairment [EMA/FDA].
Pediatric Use Generally not recommended for the pediatric population, except when managing hyperuricemia secondary to malignancy or certain hereditary enzyme disorders [Health Canada].
Reproductive Status Not recommended during pregnancy or breastfeeding (the drug and its metabolite are excreted into human milk) [NIH LactMed].

Eligibility is constrained by immunological status (hypersensitivity), organ function, and age, ensuring the drug is used only in officially established patient categories.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Alodan (Allopurinol) details interactions based on its inhibition of the Xanthine Oxidase enzyme and other pharmacodynamic effects. All factual statements are based strictly on authoritative government regulatory documentation.

High-Risk Combinations and Restrictions

Co-administration with Mercaptopurine and Azathioprine is classified as a high-risk pharmacokinetic interaction due to the significant increase in their plasma concentrations. This necessitates a mandatory dose reduction of the co-administered medicine to prevent life-threatening toxicity. Allopurinol must also be discontinued prior to and during treatment with Pegloticase.

Documented Interaction Patterns

Allopurinol is documented to increase the plasma concentration of certain substances, including Didanosine and Vidarabine, and has been reported to inhibit the metabolism of Theophylline. Conversely, co-administration with Uricosuric Agents (such as Probenecid) may accelerate the excretion of Allopurinol’s active metabolite, Oxipurinol, potentially decreasing Allopurinol’s effectiveness.

Conditional Administration

Regulatory information specifies a requirement for timing separation between Allopurinol and Aluminum Hydroxide to prevent a reduction in Allopurinol’s effect. Additionally, the risk of hypersensitivity reactions when combining Allopurinol with Thiazide Diuretics is formally noted as being increased for patients with impaired renal function.

Mechanism of Action

Blocking the Uric Acid Synthesis Pathway

The mechanism of Alodan (Allopurinol) operates through a sequence of targeted biochemical steps focused on modulating a core metabolic process. Its pharmacological activity is derived from the ability to inhibit a key enzyme responsible for the final stage of purine breakdown. The drug acts by tightly and sustainably inhibiting the enzyme Xanthine Oxidase (XO). Its active metabolite, Oxypurinol, binds to and inactivates the enzyme, which is solely responsible for converting purine precursors (Hypoxanthine and Xanthine) into Uric acid. This action results in a significant reduction of the body’s total output of Uric acid by switching off the production at its final enzymatic step.

Mobilizing Crystal Deposits via Concentration Control

The resulting, sustained decrease in systemic Uric acid concentration creates a reverse concentration gradient between the blood and tissue storage sites. This gradient acts as the physiological force that drives the slow, continuous movement of pre-existing monosodium urate crystals back into the circulation to be dissolved. The mechanism, therefore, functions by modulating Uric acid synthesis and driving the re-entry of urate from tissue stores.

Dosage and Administration Information

Alodan is administered via two official routes: oral for routine long-term management, and intravenous (IV) injection, which is typically reserved for patients unable to take oral medication or in specific urgent settings. The standard approach to starting oral Alodan therapy is to use a low initial dose, such as 100 mg once daily. The dose is then gradually adjusted, often in 100 mg increments at weekly intervals, until the required therapeutic level is achieved. Maintenance dosages usually fall within the range of 200 mg to 600 mg daily for adults.

When the prescribed daily amount exceeds 300 mg, the total dose is generally administered in divided portions throughout the day to support tolerability. Oral tablets are instructed to be taken after meals to reduce the chance of gastrointestinal irritation. A key procedural requirement is the maintenance of high daily fluid intake to ensure a urinary output of at least two to three liters. This fluid requirement supports the proper clearance of the medicine. Dosage is significantly reduced in patients with impaired kidney function, which is a standard administration constraint. For the IV formulation, the powder must be reconstituted and diluted for infusion, adhering to limits such as a final concentration not exceeding 6 mg/mL. Prophylactic use, such as for cancer-related conditions, requires starting the medication one to two days before the cytotoxic treatment begins. If a scheduled dose is missed, the standard procedure is not to take a double dose to compensate.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Alodan


Evidence for Use in Chronic Gout and Hyperuricemia Management

Research for this condition involves Randomized Controlled Trials (RCTs) and long-term observational studies. RCTs primarily measured outcomes related to systemic imbalance, specifically the percentage of patients achieving a target serum uric acid (sUA) concentration, and monitored the frequency of episodic changes like gout flare-ups. Long-term studies explored changes related to the resolution of tophi. Follow-up durations were limited in many RCTs, meaning long-term effects are not fully established using high-certainty interventional data.

Evidence for Use in Preventing Tumor Lysis Syndrome

The acute use of Alodan was evaluated in short-term trials and observational analyses. These studies monitored outcomes reflecting temporary physiological strain, specifically recording the incidence of acute metabolic complications (TLS) and tracking plasma uric acid (PUA) levels. Comparative research often describes a slower time to achieve PUA control compared to some other agents evaluated in the trials. Comparative evidence is lacking for certain high-risk subgroups in modern treatment protocols.

Evidence for Use in Preventing Recurrent Kidney Stones

Research is supported primarily by long-term observational data and systematic reviews, as dedicated, large-scale RCTs are less numerous than those for gout. Studies was studied for patients with a history of recurrent stones, and research examined the rate of new stone formation and changes in urinary uric acid concentrations. Findings indicate that the drug was associated with patterns related to a reduced risk of stone recurrence in observed populations. Certainty remains low because the majority of data is observational, meaning results apply only to the populations studied.

Evidence in Specific Patient Populations and Uncertainty

Alodan was evaluated in studies including adults with renal impairment and older adults. The risk of certain effects was observed in some studies to increase with severe renal dysfunction, and data for this population remain insufficient in certain areas. Research exploring Alodan's role in outcomes beyond uric acid control, such as outcomes monitoring physiological strain like cardiovascular health, is still emerging, and findings were mixed across different studies.

Frequently Asked Questions (FAQ)

Common questions about Alodan (FAQ)

Q: How quickly should I expect Alodan to start working?

Regulatory documents state that a decrease in the body’s uric acid levels, both in the blood and urine, generally begins within 2 to 3 days after starting Alodan. However, it may take a week or more for the full intended effects of the medicine to become apparent.


Q: Does Alodan cause weight gain or weight loss?

Weight change is not frequently listed among the common side effects of Alodan. Official safety documents mention that serious health reactions, such as severe liver problems or signs of diabetes, can sometimes involve symptoms like unusual weight loss or rapid weight gain. These potential symptoms should be discussed with a healthcare provider.


Q: What's the difference between Alodan and drug X (a well-known competitor)?

According to research overviews, both Alodan (Allopurinol) and similar competitor medicines are classified as Xanthine Oxidase Inhibitors used to reduce uric acid. Alodan has historically been studied and used primarily using a fixed-dose approach, while some newer medicines in this class have often been studied with a greater variety of adjusted doses in comparison trials.


Q: Can Alodan make me feel tired or drowsy during the day?

Official safety information notes the occasional occurrence of drowsiness or dizziness associated with the use of Alodan. Regulatory documents include a warning noting that caution should be exercised when driving or operating machinery until the individual knows how the medicine affects their alertness.


Q: Do the side effects of Alodan usually go away over time?

Regulatory-derived patient guides suggest that certain mild effects, such as initial stomach upset or the expected increase in gout flares when starting the drug, can often be managed. However, there is no universal statement confirming that all side effects will resolve automatically over time.


Q: Will taking Alodan affect my sleep?

Sleeplessness, or insomnia, is listed in detailed safety documents as a less frequent adverse reaction that has been reported with Alodan. This effect is considered uncommon.


Q: Can I take Alodan if I am also taking vitamins or herbal supplements?

Regulatory-derived patient information states that there is not enough data available to confirm whether combining Alodan with complementary medicines, herbal remedies, or supplements is safe. These products are generally not tested under the same regulatory requirements as prescription medicines.


Q: Are there any foods or drinks I should avoid completely while on Alodan?

Regulatory-derived patient information recommends avoiding alcohol, as it may worsen the underlying condition Alodan is prescribed to treat. If a special diet is recommended to help prevent kidney stones, it would be based on the specific instructions provided by a healthcare provider regarding certain foods.


Q: Can I use over-the-counter pain relievers like ibuprofen while taking Alodan?

Authoritative patient guides indicate that it is generally permissible to take Alodan alongside non-prescription anti-inflammatory pain medications such as ibuprofen. As with any combination of medicines, this usage should be reviewed by a healthcare provider.


Q: Is Alodan safe for older adults or seniors?

Alodan is intended for use in adults and has been included in studies involving older adults. Regulatory information confirms that the drug requires extra caution and/or a dose reduction in elderly patients who have reduced kidney function.


Q: Can people with liver or kidney issues use Alodan?

Patients with impaired liver or kidney function can use Alodan, but regulatory documents require that the medicine be used with caution and the dose must be significantly reduced to prevent potential accumulation and side effects.


Q: Is Alodan known to cause 'brain fog' or difficulty concentrating?

Official safety information does not use the specific term 'brain fog,' but reports of less frequent effects on the central nervous system (CNS) are noted. These can include decreased awareness, confusion, or hostility.


Q: How long does Alodan stay in your system after stopping it?

Alodan is quickly processed into its active compound, Oxipurinol, which has a half-life of 12 to 30 hours. However, uric acid levels return to pre-treatment levels slowly. It typically takes 7 to 10 days after stopping therapy for the medicine's full effect to disappear from the body.


Q: Is Alodan a type of controlled substance or does it have potential for dependence?

Regulatory classification information indicates that Alodan is not scheduled under the Controlled Substances Act. This means it is not officially classified as a controlled drug.


Q: Are there any long-term effects of taking Alodan that people should know about?

Alodan is typically a long-term treatment for chronic conditions. Aside from its intended effects in managing these conditions, regulatory-derived resources state that prolonged use has, uncommonly, been associated with an increased risk for cataracts.


Q: Does Alodan have any impact on blood pressure or heart rate?

Official adverse reaction listings include rare reports of changes in heart rate, such as a slow or irregular heartbeat, and chest pain. Furthermore, patients with pre-existing conditions like high blood pressure (hypertension) or congestive heart failure are advised to use the drug with caution.


Q: What happens if I miss a dose of Alodan (informational query only)?

If a dose is missed, regulatory-derived patient instructions advise taking it as soon as it is remembered unless it is nearly time for the next scheduled dose. If so, the missed dose should be skipped entirely. Official guidance strictly prohibits taking a double dose to compensate.


Q: Has Alodan been studied in children or teenagers?

Official labeling confirms that Alodan has been studied and is intended for use in the pediatric population only for specific, restricted conditions. These include managing hyperuricemia related to certain cancers (malignancy) or specific hereditary enzyme disorders.


Q: Are there any genetic factors that might change how Alodan works for someone?

Regulatory and pharmacogenetic guidelines note a strong association between the HLA-B*58:01 genetic variant and an increased risk of severe skin reactions. For individuals carrying this genetic marker, a healthcare provider may need to consider an alternative treatment.


Q: Can I drive or operate machinery after taking Alodan?

Regulatory documents include a warning noting that caution should be exercised when driving or operating machinery until the individual knows how the medicine affects their alertness, due to the potential for dizziness or drowsiness.


Q: What should I do if the expected effects of Alodan do not seem to be happening?

Patient guidance describes that a discussion with a healthcare provider is appropriate if expected effects do not appear to improve after a period of approximately 6 weeks of starting Alodan therapy.


Q: Is it possible for Alodan to cause anxiety or nervousness?

Official adverse reaction listings include reports of mood and behavioral changes such as anxiety, agitation, and hostility. These effects are considered rare when associated with the use of Alodan.


Q: What kind of monitoring (like blood tests) might be needed while on Alodan?

Official prescribing information notes the importance of regular monitoring while taking Alodan. This monitoring commonly includes blood counts and tests for checking kidney and liver function, particularly during the initial dose adjustment phase.


Q: How is the strength or dosage of Alodan determined generally?

The dosage of Alodan is generally determined using a 'treat-to-target' approach. This means the healthcare provider adjusts the dose (titrates it) until the patient achieves the specific goal for their serum uric acid level.


Q: Will Alodan affect my ability to get pregnant or affect fertility?

Detailed adverse reaction reports include trouble getting pregnant as a less frequent effect. Regulatory caution advises that the drug is generally not recommended during pregnancy, as the medicine and its active compound are known to pass into human milk.


Q: Does Alodan need to be taken consistently at the exact same time every day?

While consistent dosing is recommended for any long-term medicine, patient guidance on a missed dose indicates that if it is almost time for the next dose, the missed dose should be skipped. This suggests a defined window of acceptable daily administration rather than a strict requirement for the exact time.


Q: What does it mean if an interaction is listed as 'minor' or 'major' for Alodan?

In regulatory-derived drug information, interactions are commonly classified by their severity. For Alodan, these categories reflect the documented risk of potential harm (major, moderate, or minor) if the drug is combined with other substances, which dictates the level of medical management required.


Q: How long is a typical treatment course with Alodan?

For the management of chronic conditions like gout and certain types of kidney stones, Alodan is typically described as a long-term therapy. The medicine helps to control symptoms and manage the underlying condition, but it should only be stopped as directed by a healthcare provider.


Q: Does Alodan affect blood sugar levels?

Official safety information does not state that Alodan directly causes blood sugar changes. However, symptoms suggestive of diabetes, such as unusual thirst, increased urination, or unusual tiredness, are noted as serious potential side effects. Patients with pre-existing diabetes are advised to use the drug with caution.


Q: How do studies measure the success of Alodan treatment?

For its main indication in gout, research studies primarily measure the success of Alodan treatment by monitoring two key outcomes. These are whether patients achieve and maintain a specific target serum uric acid concentration, and by tracking the frequency of acute gout attacks (flares).


Q: Is there a link between Alodan and changes in mood?

Official adverse reaction listings include reports of mood-related changes, such as depression, anxiety, hostility, and agitation. These are categorized as rare effects that have been reported with the use of the medicine.

How should Alodan be stored and disposed of?

The official labeling for Alodan (Allopurinol) strictly defines storage and disposal requirements to maintain product stability and ensure safety.

Storage Requirements

Alodan oral tablets must be stored at a temperature not above 25 C and kept from freezing. The container must be kept tightly closed and the medication must remain stored in the original package to protect it from moisture. All forms of the medicine must be stored out of the sight and reach of children.

Stability and Handling

If the intravenous solution is prepared, it is crucial that the mixed product is not refrigerated and must be used within 10 hours of reconstitution.

Disposal Instructions

Unused or expired Alodan should not be discarded into wastewater. Patients must consult a healthcare professional or pharmacist for instructions on how to properly dispose of the medicine according to local pharmaceutical waste regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Alodan found in:

A-Z Index: